Barinthus Biotherapeutics
BRNS
15 hedge funds and large institutions have $9.15M invested in Barinthus Biotherapeutics in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 4 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.32% less ownership
Funds ownership: 24.9% → 23.58% (-1.3%)
6% less funds holding
Funds holding: 16 → 15 (-1)
11% less capital invested
Capital invested by funds: $10.3M → $9.15M (-$1.19M)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
+$38.5K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$26.9K |
| 3 |
Renaissance Technologies
New York
|
+$616 |
| 4 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$375 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$108 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GS
Gilead Sciences
Foster City,
California
|
-$257K |
| 2 |
IIM
Ipswich Investment Management
Beverly,
Massachusetts
|
-$21.2K |
| 3 |
Millennium Management
New York
|
-$13.2K |
| 4 |
CCG
Catalina Capital Group
Torrance,
California
|
-$12.3K |
| 5 |
Morgan Stanley
New York
|
-$7.34K |
BRNS Hedge Fund Activity: Q1 2025 in Review
15 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Barinthus Biotherapeutics (BRNS) for Q1 2025, worth a combined $9.15M — down 11% from $10.3M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BRNS and 3 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 2 added.
The largest buyer was HighTower Advisors, opening a new position worth an estimated $38.5K. The largest seller was Gilead Sciences, cutting an estimated $257K.
- 15 institutional investors held Barinthus Biotherapeutics (BRNS) as of Q1 2025, down from 16 in Q4 2024.
- Funds reported $9.15M of Barinthus Biotherapeutics stock for Q1 2025, down 11% quarter-over-quarter.
- 3 funds opened new Barinthus Biotherapeutics positions in Q1 2025 and 4 closed out, a net change of -1 holder.
- The largest Barinthus Biotherapeutics buyer in Q1 2025 was HighTower Advisors, an estimated $38.5K added.
- The largest Barinthus Biotherapeutics seller in Q1 2025 was Gilead Sciences, an estimated $257K sold.
Based on aggregated 13F filings for Q1 2025.